This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): HolaVax-ETEC
Description: HolaVax-ETEC is a vaccine against enterotoxigenic E. coli (ETEC).
Deal Structure: HolaVax-ETEC was originally developed by Acambis. In July 2008, Sanofi-aventis announced it reached an agreement with Acambis on the terms of a unanimously recommended cash offer for the entire issued and to be issued share capital of Acambis. The acqusition was completed in September 2008.
Additional information available to subscribers only: